Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.

Revenue
+19.2%
EPS
+64.1%
Free cash flow
−29.8%
Total debt
−5.19%

Quarter to September 2026, against a year earlier

146.38 9.74 −6.24%
Market cap
$10.8B
P/E
25.2×
Fwd P/E
24.4×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a

Insulet Corporation 10-K filed Feb 18, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business, against the 10-K filed Feb 21, 2025: 8 added · 25 removed · 56 modified; 5 with only figures updated

  1. Modified · Market Opportunity: Management of Diabetes

    •Type 2 diabetes, the more common form, is characterized by the body’s inability to either properly utilize insulin or produce enough insulin. Historically, type 2 diabetes has occurred in later adulthood, but its incidence is increasing among the younger populationchildren and young adults, due primarily to increasing obesity. Initially, many people with type 2 diabetes attempt to manage their diabetes with improvements in diet, exercise, and/or medications, both oral and injectable, including SGLT2 inhibitors and GLP-1 drugs. As their diabetes advances, some individuals progress to multiple drug therapies, which often include insulin therapy. People with type 2 diabetes who take insulin either require intensive insulin therapy (typically multiple injections of insulin per day) or basal (long-acting) insulin (typically a single injection daily or weekly). We estimate that approximately 6 million people have insulin-intensiveinsulin-requiring type 2 diabetes in the countries we currently serve and another 3 million people with type 2 diabetes in the United States require only long-actingbasal insulin.